Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2026-01-22 00:00:00 ET · period of report 2026-01-20 · accession 0001967150-26-000002 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2026-01-22	2026-01-20	ELVN	Lyssikatos Joseph P	CSO	S - Sale	$26.75	-20.0K	759.7K	-3%	-$535.1K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-01-20	S	D	14,509	$26.90	745,188	I See footnote	—	—	(F4) This transaction was executed in multiple trades at prices ranging from $26.6137 to $27.344. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
2	Common	Common Stock	2026-01-20	S	D	5,491	$26.37	759,697	I See footnote	—	—	(F2) This transaction was executed in multiple trades at prices ranging from $25.605 to $26.5928. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.